The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
Merck emphasized the broader significance of the findings
Subscribe To Our Newsletter & Stay Updated
